ClinicalTrials.gg
Status unknownNCT04009161Updated Aug 30, 2023

Osteoradionecrosis Rate in Patients Undergoing Radiotherapy for Head and Neck Cancer Treatment.

An observational study in Head and Neck Cancer, Osteoradionecrosis and Radiotherapy Side Effect, sponsored by Catholic University of the Sacred Heart. Status unknown at 1 site in Italy. Per ClinicalTrials.gov, last updated 2023-08-30.

Sponsored by Catholic University of the Sacred Heart · Observational

The sponsor has not verified this record recently (last verified Aug 2023), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
160
Sex
All
01

Study summary

Objectives High-dose radiotherapy (RT) for head and neck cancer has significant adverse effects on maxillofacial tissues, among which osteoradionecrosis (ORN) is the most severe and potentially life-threatening. Although tooth extractions seem to be the main risk factor, few perspective studies evaluated protocols to minimize the ORN risk due to extractions. The aim of this study is to evaluate incidence and risk factors of ORN in a cohort of patients receiving tooth extractions before RT and evaluate an algorithm about extraction decision.

Methods One-hundred ten patients were consecutively recruited in this study: impacted third molars with radiographic sign of pericoronitis, teeth with periapical lesions, unrestorable teeth, periodontally compromised teeth (pocket probing depth >5 mm, clinical attachment loss > 8 mm, grade 2 tooth mobility, II grade furcation involvement) were extracted under antibiotic prophylaxis. A 15-days interval between the last tooth extraction and the beginning of RT was recommended. Patients were visited at 15 days, 1, 3 and 6 months after the beginning of RT. Data of patients with a minimum of 6 months follow-up are presented in this report. ORN was defined as irradiated exposed necrotic bone, without healing for 3 months, in absence of cancer recurrence. The protocol was approved by the Ethic Committee of Catholic University - Fondazione Policlinico Gemelli (Prot. OHHN-1, ID-2132).

02

Conditions studied

  • Head and Neck Cancer
  • Osteoradionecrosis
  • Radiotherapy Side Effect
  • Tooth Avulsion
03

In context

Head and Neck Neoplasms

2,402 studies on the registry are indexed under Head and Neck Neoplasms; 559 are open to participants now.

This study's planned enrollment of 160 is above the median of 100 across 453 observational studies indexed under Head and Neck Neoplasms.

Browse Head and Neck Neoplasms studies →

Lead sponsor

Catholic University of the Sacred Heart is the lead sponsor of 237 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients irradiated for head and neck cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients willing to sign the informed consent form
  • Patients with diagnosis of HNC, with specific prescription of local radiotherapy, both for curative and palliative purpose, with or without chemotherapic treatment.
  • Patient with diagnosis of HNC, with specific prescription of local radiotherapy as an adjuvant to surgical resection, with or without chemotherapic treatment.

Exclusion criteria

Exclusion Criteria:

  • Patients participating to other clinical studies
  • Patients who refuse to participate in the study
  • Patients unable to attend the ambulatory visits scheduled by the protocol
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
160 participants (estimated)
Patient registry
No

Interventions

  • ProcedureTooth extraction

    Tooth extraction before the beginning of radiotherapy in patients irradiated for Head and Neck cancer

06

What researchers measure

Primary outcomes

  1. Osteoradionecrosis Incidence

    To evaluate the ORN incidence in a population irradiated for Head and Neck Cancer.

    Time frame: 60 months after the beginning of RT

  2. Osteoradionecrosis rate following pre-radiotherapy tooth extraction

    Time frame: 60 months after the beginning of RT

Secondary outcomes

  1. Extraction site: number of tooth extractions for each site (anterior and posterior maxilla or mandible and specific tooth number) and percentage of ORN for each site.

    Risk of ORN per extraction site

    Time frame: 60 months after the beginning of RT

  2. Time interval between extraction and Radiotherapy: days between every tooth extraction and the beginning of RT.

    To understand the relationship between this time-lapse and the ORN incidence

    Time frame: 60 months after the beginning of RT

  3. Surgical protocol 1: Flap elevation per each extracted tooth (YES/NO) and percentage of ORN per each type of procedure.

    Tooth extraction related risk factors

    Time frame: 60 months after the beginning of RT

  4. Surgical protocol 2: Primary intention closure achievement per post-extractive site (YES/NO) and percentage of ORN per each type of procedure.

    Tooth extraction related risk factors

    Time frame: 60 months after the beginning of RT

  5. Surgical protocol 3: Osteotomy per each extracted tooth (YES/NO) and percentage of ORN per each type of procedure.

    Tooth extraction related risk factors

    Time frame: 60 months after the beginning of RT

  6. Reason for tooth extraction: number of tooth extraction for each cause under the protocol (caries, periodontal disease, endodontic lesions, pericoronitis, fracture) and percentage of ORN for each cause.

    Tooth extraction related risk factors

    Time frame: 60 months after the beginning of RT

  7. Radiation dose to the post-extractive site (Gy of radiation received by every post-extractive site)

    Tooth extraction related risk factors

    Time frame: 60 months after the beginning of RT

  8. Age of every patients at the beginning of RT

    ORN risk factors

    Time frame: At baseline

  9. Sex (male, female) of every patients at the beginning of RT

    ORN risk factors

    Time frame: At baseline

  10. Number of participants undergoing concurrent chemotherapy (neoadjuvant or concomitant)

    ORN risk factors

    Time frame: During treatment

07

Study locations

1 site
  • Catholic University of the Sacred Heart
    Rome, 00168, Italy
08

References and documents

Publications

  • Rupe C, Gioco G, Tranfa M, Scilla F, Schiavelli A, Cairo F, Galli J, Scambia G, Rengo C, Lajolo C. Differences in oral health status between cancer patients: a case-control observational study. BMC Oral Health. 2025 Dec 1;25(1):1862. doi: 10.1186/s12903-025-06963-7. PubMed 41327109 ↗
  • Rupe C, Gioco G, Massaccesi M, Tagliaferri L, Pastore F, Micciche F, Galli J, Mele D, Specchia ML, Cassano A, Cordaro M, Lajolo C. Osteoradionecrosis incidence in pre-radiation teeth extractions: A prospective study. Oral Dis. 2024 Nov;30(8):5129-5139. doi: 10.1111/odi.14941. Epub 2024 Apr 9. PubMed 38591808 ↗
  • Rupe C, Gioco G, Almadori G, Galli J, Micciche F, Olivieri M, Cordaro M, Lajolo C. Oral Candida spp. Colonisation Is a Risk Factor for Severe Oral Mucositis in Patients Undergoing Radiotherapy for Head & Neck Cancer: Results from a Multidisciplinary Mono-Institutional Prospective Observational Study. Cancers (Basel). 2022 Sep 29;14(19):4746. doi: 10.3390/cancers14194746. PubMed 36230669 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04009161
Responsible party
Carlo Lajolo (Principal Investigator, Catholic University of the Sacred Heart) — Principal investigator
First posted
Jul 5, 2019
Start date
Mar 14, 2017
Primary completion
Jun 1, 2023
Completion
Jun 1, 2025 (estimated)
Last update
Aug 30, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion